Cirmtuzumab
Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.[1][2]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized |
Target | ROR1 |
Clinical data | |
Other names | UC-961 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).[3][4]
References
- Choi; et al. (2015). "Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts". Cite journal requires
|journal=
(help) - Researchers to test novel drug combination against toughest breast cancers August 2018
- A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
- Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia Choi 2018
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.